| Abstract | The problems of long-term levodopa treatment are well established, and a number of studies describe the use of bromocriptine as a first-line agent in patients under 65 years. This multicentre double-blind study compared the efficacy of low and very low dose bromocriptine in 64 elderly subjects with newly diagnosed Parkinson's disease. Both regimens led to clinical improvement, but there was a high drop-out rate and a high mortality. These difficulties, together with a low recruitment rate, resulted in problems of statistical analysis. There was no significant advantage in using the higher of the two dosage regimens, and we would recommend a maintenance dosage range of 5 mg-15 mg bromocriptine daily. On the basis of this study, however, bromocriptine seems unlikely to replace levodopa as the first-line treatment for Parkinson's disease. |
| Authors | |
| Journal | Age and ageing
(Age Ageing)
Vol. 19
Issue 1
Pg. 62-7
(Jan 1990)
ISSN: 0002-0729 ENGLAND |
| PMID | 2180259
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study)
|
| Chemical References |
|
| Topics |
- Aged
- Aged, 80 and over
- Bromocriptine
(administration & dosage, therapeutic use)
- Double-Blind Method
- Drug Evaluation
- Female
- Humans
- Male
- Middle Aged
- Multicenter Studies as Topic
- Parkinson Disease
(diagnosis, drug therapy)
|
